135 demonstrated that the primary endpoint change from baseline in the North Star Ambulatory Assessment (NSAA) score did not reach statistical significance between DMD patients after a single intravenous administration of delandistrogene moxeparvovec (1.33 × 10 14 vector genomes per kilogram of body weight; vg/kg; n = 63) and the placebo group ( n = 62).
1
—
—